Latest Safety News

Beetaloo Energy has received a $15.4 million R&D tax refund, reinforcing its financial position as it advances key milestones in the Carpentaria Pilot Project towards gas production and sales in 2026.

Arovella Therapeutics has demonstrated that its novel CLDN18.2-targeting CAR incorporated into iNKT cells effectively eliminates pancreatic and gastric cancer cells in vitro, with IL-12-TM armouring enhancing potency and durability.

AdAlta’s BZDS1901 CAR-T therapy shows remarkable tumour shrinkage and complete responses in advanced mesothelioma patients, doubling expected outcomes and paving the way for higher dosing and expanded trials.

Actinogen Medical has initiated the open-label extension of its XanaMIA Alzheimer’s trial, offering all participants active Xanamem treatment for up to 25 months to gather long-term safety and efficacy data ahead of final trial results.

GoldArc Resources has secured a key tenement adjacent to its high-grade Whistler and Woodpecker South prospects in the Kookynie Goldfields, expanding its Leonora South project at a modest cost. This acquisition complements ongoing drilling programs that have already delivered impressive gold assay results.

Racura Oncology has enrolled the first patient in its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib to tackle resistance in EGFR-mutant non-small cell lung cancer. This milestone sets the stage for a multi-centre study aiming to improve treatment outcomes.

ARN Media is confronting a substantial legal claim from former contractor Jacqueline Henderson, who alleges adverse action and bullying following her contract termination. The case also challenges previous ASX disclosures, with compensation sought exceeding $82 million.

ClearVue Technologies has achieved a key international certification for its innovative solar panels and is deepening its strategic alliance with Helios Power, setting the stage for expanded commercial deployment in the building-integrated photovoltaics market.

Paradigm Biopharmaceuticals has achieved 50% patient enrolment in its pivotal Phase 3 trial for injectable pentosan polysulfate sodium, advancing steadily towards an interim analysis expected in August 2026.

Patrys Limited is advancing a proprietary injectable formulation of quetiapine aimed at the large and underserved delirium treatment market, leveraging an accelerated FDA approval pathway and extensive existing safety data.

Alterity Therapeutics has secured encouraging regulatory feedback from the FDA on its ATH434 Phase 3 program for Multiple System Atrophy, marking a critical step towards pivotal trial initiation.

Aroa Biosurgery has completed its Symphony randomised controlled trial, demonstrating improved healing rates for diabetic foot ulcers compared to standard care. The preliminary results pave the way for clinical adoption and potential US reimbursement.